Home
/
Niagen Bioscience, Inc.
/
Financials
/
Quarterly
Niagen Bioscience, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Niagen Bioscience, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$33.99M
Nov 4, 2025
Q2
2025
Jun 30, 2025
$31.12M
Aug 6, 2025
Q1
2025
Mar 31, 2025
$30.48M
May 7, 2025
Q3
2025
Sep 30, 2024
$25.58M
Nov 4, 2025
Q2
2025
Jun 30, 2024
$22.74M
Aug 6, 2025
Q1
2025
Mar 31, 2024
$22.15M
May 7, 2025
Q3
2024
Sep 30, 2023
$19.50M
Oct 31, 2024
Q2
2024
Jun 30, 2023
$20.32M
Aug 7, 2024
Q1
2024
Mar 31, 2023
$22.56M
May 8, 2024
Q3
2023
Sep 30, 2022
$17.06M
Nov 8, 2023
Q2
2023
Jun 30, 2022
$16.73M
Aug 9, 2023
Q1
2023
Mar 31, 2022
$17.26M
May 10, 2023
Q3
2022
Sep 30, 2021
$17.31M
Nov 2, 2022
Q2
2022
Jun 30, 2021
$17.70M
Aug 10, 2022
Q1
2022
Mar 31, 2021
$14.68M
May 12, 2022
Q3
2021
Sep 30, 2020
$14.18M
Nov 3, 2021
Q2
2021
Jun 30, 2020
$15.29M
Aug 3, 2021
Q1
2021
Mar 31, 2020
$14.35M
May 6, 2021
Q3
2020
Sep 30, 2019
$12.05M
Nov 4, 2020
Q2
2020
Jun 30, 2019
$11.10M
Aug 6, 2020
Revenue (Net Sales) — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2011
Oct 1, 2011
$1.83M
Nov 10, 2011
Q3
2011
Oct 2, 2010
$1.56M
Nov 10, 2011
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$4.58M
Nov 4, 2025
Q2
2025
Jun 30, 2025
$3.61M
Aug 6, 2025
Q1
2025
Mar 31, 2025
$5.06M
May 7, 2025
Q3
2025
Sep 30, 2024
$1.88M
Nov 4, 2025
Q2
2025
Jun 30, 2024
($15.0K)
Aug 6, 2025
Q1
2025
Mar 31, 2024
($492.0K)
May 7, 2025
Q3
2024
Sep 30, 2023
($959.0K)
Oct 31, 2024
Q2
2024
Jun 30, 2023
($2.19M)
Aug 7, 2024
Q1
2024
Mar 31, 2023
($1.90M)
May 8, 2024
Q3
2023
Sep 30, 2022
($985.0K)
Nov 8, 2023
Q2
2023
Jun 30, 2022
($6.40M)
Aug 9, 2023
Q1
2023
Mar 31, 2022
($7.74M)
May 10, 2023
Q3
2022
Sep 30, 2021
($8.86M)
Nov 2, 2022
Q2
2022
Jun 30, 2021
($5.57M)
Aug 10, 2022
Q1
2022
Mar 31, 2021
($7.38M)
May 12, 2022
Q3
2021
Sep 30, 2020
($4.22M)
Nov 3, 2021
Q2
2021
Jun 30, 2020
($3.71M)
Aug 3, 2021
Q1
2021
Mar 31, 2020
($5.90M)
May 6, 2021
Q3
2020
Sep 30, 2019
($7.20M)
Nov 4, 2020
Q2
2020
Jun 30, 2019
($7.76M)
Aug 6, 2020
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$4.24M
Nov 4, 2025
Q2
2025
Jun 30, 2025
$3.19M
Aug 6, 2025
Q1
2025
Mar 31, 2025
$4.77M
May 7, 2025
Q3
2025
Sep 30, 2024
$1.60M
Nov 4, 2025
Q2
2025
Jun 30, 2024
($256.0K)
Aug 6, 2025
Q1
2025
Mar 31, 2024
($731.0K)
May 7, 2025
Q3
2024
Sep 30, 2023
($1.15M)
Oct 31, 2024
Q2
2024
Jun 30, 2023
($2.32M)
Aug 7, 2024
Q1
2024
Mar 31, 2023
($1.97M)
May 8, 2024
Q3
2023
Sep 30, 2022
($3.07M)
Nov 8, 2023
Q2
2023
Jun 30, 2022
($6.39M)
Aug 9, 2023
Q1
2023
Mar 31, 2022
($7.73M)
May 10, 2023
Q3
2022
Sep 30, 2021
($8.84M)
Nov 2, 2022
Q2
2022
Jun 30, 2021
($5.55M)
Aug 10, 2022
Q1
2022
Mar 31, 2021
($7.36M)
May 12, 2022
Q3
2021
Sep 30, 2020
($4.20M)
Nov 3, 2021
Q2
2021
Jun 30, 2020
($3.69M)
Aug 3, 2021
Q1
2021
Mar 31, 2020
($5.89M)
May 6, 2021
Q3
2020
Sep 30, 2019
($6.89M)
Nov 4, 2020
Q2
2020
Jun 30, 2019
($7.18M)
Aug 6, 2020